HC Wainwright raises target for Kodiak Sciences stock to USD 126.00

Published on 10/15/2026 at 21:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter loss reached USD 1.05 per share. Kodiak Sciences stock costs EUR 77.04 on October 15, 2026, up 6.63 percent on Nasdaq.

Analyst view meets earnings date

On October 12, 2026, HC Wainwright set a USD 126.00 target for Kodiak Sciences.
Second-quarter loss reached USD 1.05 per share.
Kodiak Sciences stock costs EUR 77.04 at Lang & Schwarz on October 15, 2026 at 9:12 p.m. CEST, up 6.63 percent on Nasdaq.
Q3 2026 results are estimated for November 12, 2026.

KOD, US50015M1099, Illustration mit AI erstellt.

HC Wainwright raised its target for Kodiak Sciences stock from USD 96.00 to USD 126.00 on October 12, 2026, and kept a Buy rating, according to MarketBeat. The target stood 45.72 percent above the USD 86.47 Nasdaq price. Kodiak Sciences was trading at EUR 77.04 at Lang & Schwarz on October 15, 2026 at 9:12 p.m. CEST, up 6.63 percent on Nasdaq.

Second-quarter loss stays central

For the second quarter of 2026, Kodiak reported a consolidated net loss of USD 65.64 million and basic earnings per share of minus USD 1.05. The earnings-per-share figure missed the USD 0.96 consensus loss by USD 0.09, as reported by MarketBeat. Kodiak's investor-relations materials describe the company as a clinical-stage biotechnology business focused on retinal medicines and list Nasdaq as its exchange, according to Kodiak Sciences.

Stock position after the move

The Nasdaq quote was USD 86.47 at 3:17 p.m. ET on October 15, 2026, with a same-day gain of 6.63 percent. Trading volume was 932,734 shares against an average volume of 1,634,157 shares. The 52-week range was USD 13.95 to USD 104.00, leaving the quote 16.83 percent below the high and 519.50 percent above the low.

Valuation and next report

Kodiak's market capitalization was USD 5.4 billion and its negative price-to-earnings ratio was minus 20.65 on October 15, 2026. The company paid no dividend yield in the same quote. Kodiak Sciences is estimated to report third-quarter 2026 results on November 12, 2026, after the market closes, with a conference call scheduled for 4:00 p.m. ET, according to MarketBeat.

Comparison with peers

KOD (Nasdaq, USD): plus 6.63 percent, P/E minus 20.65, market capitalization USD 5.4 billion.

Regeneron Pharmaceuticals (Nasdaq, USD): plus 2.70 percent, P/E 19.76, market capitalization USD 82.3 billion.

Alnylam Pharmaceuticals (Nasdaq, USD): plus 3.38 percent, P/E 39.20, market capitalization USD 31.1 billion.

Price and investor calendar

The higher analyst target gives Kodiak a dated valuation marker, while the next earnings date supplies the next scheduled checkpoint. The company remains in clinical development, so quarterly losses and trial execution remain material to the stock's valuation.

Kodiak Sciences was trading at EUR 77.04 at Lang & Schwarz on October 15, 2026 at 9:12 p.m. CEST, with a 6.63 percent gain on Nasdaq. The further course of trading is shown by the continuously updated real-time quote of Kodiak Sciences stock.